[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100308614":3},{"organization":4,"armGroups":7,"interventions":78,"overallOfficials":137,"centralContacts":145,"locations":151,"responsibleParty":291,"collaborators":293,"id":305,"slug":306,"hasResults":307,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":307,"sex":313,"minAge":314,"maxAge":84,"enrollmentInfo":315,"targetDuration":84,"studyType":318,"phases":319,"briefSummary":321,"conditions":322,"keywords":84,"overallStatus":154,"whyStopped":84,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":335},{"fullName":5,"class":6},"Canadian Cancer Trials Group","NETWORK",[8,14,19,24,29,34,39,44,49,54,59,64,69,74],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 - Arm CLOSED, no patients recruited","EXPERIMENTAL","VEGFR1, VEGFR2, VEGFR3",[13],"Drug: Axitinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2 - Arm CLOSED, no patients recruited","BCR-ABL, SRC",[18],"Drug: Bosutinib",{"label":20,"type":10,"description":21,"interventionNames":22},"Group 3 - Arm CLOSED","ALK, ROS1, MET",[23],"Drug: Crizotinib",{"label":25,"type":10,"description":26,"interventionNames":27},"Group 4 - Arm CLOSED, no patients recruited","KIT, PDGFRA, PDGFRB, ABL1",[28],"Drug: Dasatinib",{"label":30,"type":10,"description":31,"interventionNames":32},"Group 5 - Arm CLOSED","EGFR",[33],"Drug: Erlotinib",{"label":35,"type":10,"description":36,"interventionNames":37},"Group 6 - Arm CLOSED","high mutation burden, POLE, POLD1",[38],"Drug: Nivolumab plus Ipilimumab",{"label":40,"type":10,"description":41,"interventionNames":42},"Group 7 - Arm CLOSED","BRCA1, BRCA2, mutations in HRD",[43],"Drug: Olaparib",{"label":45,"type":10,"description":46,"interventionNames":47},"Group 8 - Arm CLOSED","CDKN2A, CDK4, CCND1, SMARCA4",[48],"Drug: Palbociclib",{"label":50,"type":10,"description":51,"interventionNames":52},"Group 9 Arm CLOSED","CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL",[53],"Drug: Sunitinib",{"label":55,"type":10,"description":56,"interventionNames":57},"Group 10 Arm CLOSED","AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2",[58],"Drug: Temsirolimus",{"label":60,"type":10,"description":61,"interventionNames":62},"Group 11 - Arm CLOSED","ERBB2",[63],"Drug: Trastuzumab plus Pertuzumab",{"label":65,"type":10,"description":66,"interventionNames":67},"Group 12 - Arm CLOSED","BRAFV600",[68],"Drug: Vemurafenib plus Cobimetinib",{"label":70,"type":10,"description":71,"interventionNames":72},"Group 13 - Arm CLOSED","PTCH1, SMO",[73],"Drug: Vismodegib",{"label":75,"type":10,"description":61,"interventionNames":76},"Group 14",[77],"Drug: Tucatinib",[79,85,89,93,97,101,105,109,113,117,121,125,129,133],{"type":80,"name":81,"description":82,"armGroupLabels":83,"otherNames":84},"DRUG","Olaparib","300mg taken twice daily",[40],null,{"type":80,"name":86,"description":87,"armGroupLabels":88,"otherNames":84},"Dasatinib","100mg administered orally once daily",[25],{"type":80,"name":90,"description":91,"armGroupLabels":92,"otherNames":84},"Nivolumab plus Ipilimumab","* Combination Phase - 3mg\u002Fkg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg\u002Fkg administered intravenously over 30 minutes, followed by the single-agent phase.\n* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.",[35],{"type":80,"name":94,"description":95,"armGroupLabels":96,"otherNames":84},"Axitinib","5mg orally twice daily",[9],{"type":80,"name":98,"description":99,"armGroupLabels":100,"otherNames":84},"Bosutinib","500mg orally once daily",[15],{"type":80,"name":102,"description":103,"armGroupLabels":104,"otherNames":84},"Crizotinib","250mg orally twice daily",[20],{"type":80,"name":106,"description":107,"armGroupLabels":108,"otherNames":84},"Palbociclib","125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days",[45],{"type":80,"name":110,"description":111,"armGroupLabels":112,"otherNames":84},"Sunitinib","50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off",[50],{"type":80,"name":114,"description":115,"armGroupLabels":116,"otherNames":84},"Temsirolimus","25mg infused over a 30-60 minute period once a week",[55],{"type":80,"name":118,"description":119,"armGroupLabels":120,"otherNames":84},"Erlotinib","150mg orally, once daily",[30],{"type":80,"name":122,"description":123,"armGroupLabels":124,"otherNames":84},"Trastuzumab plus Pertuzumab","Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg\u002Fkg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg\u002Fkg administered as 90-minute infusion.\n\nPertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.",[60],{"type":80,"name":126,"description":127,"armGroupLabels":128,"otherNames":84},"Vemurafenib plus Cobimetinib","Vemurafenib = 960 mg orally every 12 hours.\n\nCobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest",[65],{"type":80,"name":130,"description":131,"armGroupLabels":132,"otherNames":84},"Vismodegib","150mg taken orally, once daily",[70],{"type":80,"name":134,"description":135,"armGroupLabels":136,"otherNames":84},"Tucatinib","300mg taken orally, twice daily",[75],[138,142],{"name":139,"affiliation":140,"role":141},"Lillian Siu","Univ. Health Network-OCI\u002FPrincess Margaret Hospital, Toronto, ON Canada","STUDY_CHAIR",{"name":143,"affiliation":144,"role":141},"Daniel J Renouf","BCCA - Vancouver Cancer Centre, Vancouver BC, Canada",[146],{"name":147,"role":148,"phone":149,"phoneExt":84,"email":150},"Janet Dancey","CONTACT","613-533-6430","jdancey@ctg.queensu.ca",[152,170,184,198,211,224,238,250,264,278],{"facility":153,"status":154,"city":155,"state":156,"zip":157,"country":158,"countryCode":159,"cosmosGeoPoint":160,"geoPoint":165,"contacts":166},"Cross Cancer Institute","RECRUITING","Edmonton","Alberta","T6G 1Z2","Canada","CA",{"type":161,"coordinates":162},"Point",[163,164],-113.46871,53.55014,{"lat":164,"lon":163},[167],{"name":168,"role":148,"phone":169,"phoneExt":84,"email":84},"Quincy Chu","780 432-8248",{"facility":171,"status":154,"city":172,"state":173,"zip":174,"country":158,"countryCode":159,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"BCCA - Kelowna","Kelowna","British Columbia","V1Y 5L3",{"type":161,"coordinates":176},[177,178],-119.48568,49.88307,{"lat":178,"lon":177},[181],{"name":182,"role":148,"phone":183,"phoneExt":84,"email":84},"Sara Kristina Taylor","250 712-3996",{"facility":185,"status":154,"city":186,"state":173,"zip":187,"country":158,"countryCode":159,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"BCCA - Vancouver","Vancouver","V5Z 4E6",{"type":161,"coordinates":189},[190,191],-123.11934,49.24966,{"lat":191,"lon":190},[194],{"name":195,"role":148,"phone":196,"phoneExt":197,"email":84},"Daniel John Renouf","604 877-6000","672357",{"facility":199,"status":154,"city":200,"state":201,"zip":202,"country":158,"countryCode":159,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Kingston Health Sciences Centre","Kingston","Ontario","K7L 2V7",{"type":161,"coordinates":204},[205,206],-76.48098,44.22976,{"lat":206,"lon":205},[209],{"name":210,"role":148,"phone":84,"phoneExt":84,"email":84},"Francisco Vera-Badillo",{"facility":212,"status":154,"city":213,"state":201,"zip":214,"country":158,"countryCode":159,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"London Health Sciences Centre Research Inc.","London","N6A 5W9",{"type":161,"coordinates":216},[217,218],-81.23304,42.98339,{"lat":218,"lon":217},[221],{"name":222,"role":148,"phone":223,"phoneExt":84,"email":84},"Stephen Welch","519 685-8640",{"facility":225,"status":154,"city":226,"state":201,"zip":227,"country":158,"countryCode":159,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"Ottawa Hospital Research Institute","Ottawa","K1H 8L6",{"type":161,"coordinates":229},[230,231],-75.69812,45.41117,{"lat":231,"lon":230},[234],{"name":235,"role":148,"phone":236,"phoneExt":237,"email":84},"John Hilton","613 737-7700","75086",{"facility":239,"status":154,"city":240,"state":201,"zip":241,"country":158,"countryCode":159,"cosmosGeoPoint":242,"geoPoint":246,"contacts":247},"University Health Network","Toronto","M5G 2M9",{"type":161,"coordinates":243},[244,245],-79.39864,43.70643,{"lat":245,"lon":244},[248],{"name":139,"role":148,"phone":249,"phoneExt":84,"email":84},"416 946-2911",{"facility":251,"status":154,"city":252,"state":253,"zip":254,"country":158,"countryCode":159,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"The Jewish General Hospital","Montreal","Quebec","H3T 1E2",{"type":161,"coordinates":256},[257,258],-73.58781,45.50884,{"lat":258,"lon":257},[261],{"name":262,"role":148,"phone":263,"phoneExt":84,"email":84},"Cristiano Ferrario","514 398-8307",{"facility":265,"status":154,"city":266,"state":267,"zip":268,"country":158,"countryCode":159,"cosmosGeoPoint":269,"geoPoint":273,"contacts":274},"Allan Blair Cancer Centre","Regina","Saskatchewan","S4T 7T1",{"type":161,"coordinates":270},[271,272],-104.6178,50.45008,{"lat":272,"lon":271},[275],{"name":276,"role":148,"phone":277,"phoneExt":84,"email":84},"Kimberly Hagel","306 766-2691",{"facility":279,"status":154,"city":280,"state":267,"zip":281,"country":158,"countryCode":159,"cosmosGeoPoint":282,"geoPoint":286,"contacts":287},"Saskatoon Cancer Centre","Saskatoon","S7N 4H4",{"type":161,"coordinates":283},[284,285],-106.66892,52.13238,{"lat":285,"lon":284},[288],{"name":289,"role":148,"phone":290,"phoneExt":84,"email":84},"Sunil K. Yadav","306 655-2710",{"type":292,"investigatorFullName":84,"investigatorTitle":84,"investigatorAffiliation":84,"oldNameTitle":84,"oldOrganization":84},"SPONSOR",[294,297,299,301,303],{"name":295,"class":296},"AstraZeneca","INDUSTRY",{"name":298,"class":296},"Bristol-Myers Squibb",{"name":300,"class":296},"Hoffmann-La Roche",{"name":302,"class":296},"Pfizer",{"name":304,"class":296},"Seagen Inc.","100308614","phase-2-canadian-profiling-and-targeted-agent-utilization-trial-captur-100308614",false,"NCT03297606","Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial","CAPTUR","Inclusion Criteria: (screening step - non-drug specific)\n\n* Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment known to prolong life, or who has refused such treatment.\n* ECOG performance status 0-2.\n* Patients must have normal organ function as follows:\n\n  * Absolute neutrophil count: ≥ 1.5 x 10\\^9\u002FL for solid tumours; ≥ 1.0 x 10\\^9\u002FL for neurologic malignancies\n  * Platelets ≥ 75 x 10\\^9\u002FL (or ≥ 50 x 10\\^9\u002FL if bone marrow involvement by myeloma or lymphoma).\n  * Total bilirubin ≤ 1.5 x UNL.\n  * AST (SGOT)\u002FALT (SGPT) ≤ 2.5 x institutional upper limit of normal value unless liver metastases are present in which case they must be \\\u003C 5 x ULN;\n  * Serum creatinine ≤ 1.5 x UNL or calculated or measured creatinine clearance ≥ 50mg\u002Fmin\u002F1.73µ\\^2\n* Patients must have measurable disease\n* Results must be available from tumour genomic or protein expression testing (if used to identify genetic variants), from one of the initiatives \u002F groups listed in protocol Appendix VII. The test may have been performed on the primary tumour or a metastatic deposit (including bone marrow), or blood, in a diagnostic or research laboratory and must reveal a potentially actionable variant.\n* Patient consent (Main Study Consent for the screening step) must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to the screening step to document their willingness to participate\n* Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre or a CCTG IND site. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.\n* Women\u002Fmen of childbearing potential must have agreed to use a highly effective contraceptive method.\n\nExclusion Criteria: (screening step - non-drug specific)\n\n* Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with ongoing toxicity ≥ CTCAE grade 2, other than peripheral neuropathy or asymptomatic, corrected biochemical toxicities (e.g. hypothyroidism corrected by thyroid replacement), related to prior anti-tumour treatment. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.\n* Patients concurrently receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g. megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate cancer. These medications must have been started ≥ one month prior to enrollment on this study. Patients may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific ineligibility criteria.\n* Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within one month prior to screening. All patients with previously treated brain metastases must be stable (clinically and radiologically) for at least one month after completion of treatment and either off steroid treatment or only taking physiological doses of steroids prior to the screening step.\n* Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.\n* Patients with known left ventricular ejection fraction (LVEF) \\\u003C 40%.\n* Patients with stroke (including TIA) or acute myocardial infarction within three months prior to the screening step.\n* Patients with acute gastrointestinal bleeding within one month prior to the screening step.\n* Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness\u002Fsocial situations.\n* Lactating and nursing women\n* Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician.","ALL","18 Years",{"count":316,"type":317},720,"ESTIMATED","INTERVENTIONAL",[320],"PHASE2","Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.",[323,324,325],"Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors","2026-03-24",{"date":328,"type":329},"2026-03-27","ACTUAL",{"date":331,"type":329},"2018-03-23",{"date":333,"type":317},"2027-01-31",{"name":5,"class":6},10]